X0407 4 2023-03-20 0 0001534133 CalciMedica, Inc. /DE/ CALC 0001968792 Dunn Michael J. C/O CALCIMEDICA, INC. 505 COAST S. BLVD. #202 LA JOLLA CA 92037 0 1 0 0 President and COO 0 Employee Stock Option (right to buy) 1.39 2023-03-20 4 A 0 11761 A 2024-10-01 Common Stock 11761 11761 D Employee Stock Option (right to buy) 2.44 2023-03-20 4 A 0 22777 A 2028-08-01 Common Stock 22777 22777 D Employee Stock Option (right to buy) 2.44 2023-03-20 4 A 0 8640 A 2029-04-24 Common Stock 8640 8640 D Employee Stock Option (right to buy) 6.60 2023-03-20 4 A 0 23589 A 2030-06-29 Common Stock 23589 23589 D Employee Stock Option (right to buy) 7.99 2023-03-20 4 A 0 7915 A 2031-04-27 Common Stock 7915 7915 D Employee Stock Option (right to buy) 7.99 2023-03-20 4 A 0 13147 A 2031-04-27 Common Stock 13147 13147 D Employee Stock Option (right to buy) 7.99 2023-03-20 4 A 0 7915 A 2031-06-30 Common Stock 7915 7915 D Employee Stock Option (right to buy) 10.42 2023-03-20 4 A 0 1323 A 2032-08-30 Common Stock 1323 1323 D Employee Stock Option (right to buy) 10.42 2023-03-20 4 A 0 1954 A 2032-08-30 Common Stock 1954 1954 D Employee Stock Option (right to buy) 17.34 2023-03-20 4 A 0 24747 A 2033-03-19 Common Stock 24747 24747 D Employee Stock Option (right to buy) 17.34 2023-03-20 4 A 0 847 A 2023-03-19 Common Stock 847 847 D Immediately exercisable. Received in exchange for a stock option to acquire 408,402 shares of common stock of CalciMedica, Inc. ("CalciMedica") pursuant to an Agreement and Plan of Merger and Reorganization (the "Merger Agreement") by and among CalciMedica, the Issuer and Camaro Merger Sub, Inc., a wholly-owned subsidiary of the Issuer ("Merger Sub"). Under the terms of the Merger Agreement, on March 20, 2023, Merger Sub merged with and into CalciMedica (the "Merger"), with CalciMedica surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each outstanding option to purchase shares of CalciMedica common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock. Subsequent to the Merger, the name of the Issuer was changed from Graybug Vision, Inc. to CalciMedica, Inc. Received in exchange for a stock option to acquire 790,880 shares of common stock of CalciMedica pursuant to the Merger Agreement. Upon the closing of the Merger, each outstanding option to purchase shares of CalciMedica common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock. 25% of the shares subject to the option vested on April 30, 2020 and the balance of the shares vest in a series of thirty-six (36) successive equal monthly installments thereafter. Received in exchange for a stock option to acquire 300,000 shares of common stock of CalciMedica pursuant to the Merger Agreement. 25% of the shares subject to the option vested on June 30, 2020 and the balance of the shares vest in a series of thirty-six (36) successive equal monthly installments thereafter. Received in exchange for a stock option to acquire 819,064 shares of common stock of CalciMedica pursuant to the Merger Agreement. Beginning on February 22, 2021, the shares subject to the option vest in a series of forty-eight (48) successive equal monthly installments. Received in exchange for a stock option to acquire 274,848 shares of common stock of CalciMedica pursuant to the Merger Agreement. Received in exchange for a stock option to acquire 456,522 shares of common stock of CalciMedica pursuant to the Merger Agreement. Received in exchange for a stock option to acquire 45,955 shares of common stock of CalciMedica pursuant to the Merger Agreement. Received in exchange for a stock option to acquire 67,873 shares of common stock of CalciMedica pursuant to the Merger Agreement. Beginning on November 22, 2022, the shares subject to the option vest in a series of forty-eight (48) successive equal monthly installments. Received in exchange for a stock option to acquire 859,280 shares of common stock of CalciMedica pursuant to the Merger Agreement. Received in exchange for a stock option to acquire 29,420 shares of common stock of CalciMedica pursuant to the Merger Agreement. By John Dunn, Attorney-in-Fact 2023-03-22